The hepatocyte epidermal growth factor receptor (EGFR) pathway regulates the cellular interactome within the liver fibrotic niche
- PMID: 38872438
- DOI: 10.1002/path.6299
The hepatocyte epidermal growth factor receptor (EGFR) pathway regulates the cellular interactome within the liver fibrotic niche
Abstract
Liver fibrosis is the consequence of chronic liver injury in the presence of an inflammatory component. Although the main executors of this activation are known, the mechanisms that lead to the inflammatory process that mediates the production of pro-fibrotic factors are not well characterized. Epidermal growth factor receptor (EGFR) signaling in hepatocytes is essential for the regenerative processes of the liver; however, its potential role in regulating the fibrotic niche is not yet clear. Our group generated a mouse model that expresses an inactive truncated form of the EGFR specifically in hepatocytes (ΔEGFR mice). Here, we have analyzed the response of WT and ΔEGFR mice to chronic treatment with carbon tetrachloride (CCl4), which induces a pro-inflammatory and fibrotic process in the liver. The results indicated that the hallmarks of liver fibrosis were attenuated in CCl4-treated ΔEGFR mice when compared with CCl4-treated WT mice, coinciding with a faster resolution of the fibrotic process and ameliorated damage. The absence of EGFR activity in hepatocytes induced changes in the pattern of immune cells in the liver, with a notable increase in the population of M2 macrophages, more related to fibrosis resolution, as well as in the population of lymphocytes related to eradication of the damage. Transcriptome analysis of hepatocytes, and secretome studies of extracellular media from in vitro experiments, allowed us to elucidate the specific molecular mechanisms regulated by EGFR that mediate hepatocyte production of both pro-fibrotic and pro-inflammatory mediators; these have consequences for the deposition of extracellular matrix proteins, as well as for the immune microenvironment. Overall, our study uncovered novel mechanistic insights regarding EGFR kinase-dependent actions in hepatocytes that reveal its key role in chronic liver damage. © 2024 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.
Keywords: CCl4; cytokines; extracellular matrix; immune microenvironment; inflammatory response; intercellular crosstalk; liver damage; liver fibrosis; macrophages; secretome.
© 2024 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.
References
-
- Kisseleva T, Brenner D. Molecular and cellular mechanisms of liver fibrosis and its regression. Nat Rev Gastroenterol Hepatol 2021; 18: 151–166.
-
- Fabregat I, Caballero‐Díaz D. Transforming growth factor‐β‐induced cell plasticity in liver fibrosis and hepatocarcinogenesis. Front Oncol 2018; 8: 357.
-
- Bhushan B, Michalopoulos GK. Role of epidermal growth factor receptor in liver injury and lipid metabolism: emerging new roles for an old receptor. Chem Biol Interact 2020; 324: 109090.
-
- Berasain C, Avila MA. The EGFR signalling system in the liver: from hepatoprotection to hepatocarcinogenesis. J Gastroenterol 2014; 49: 9–23.
-
- Bhushan B, Banerjee S, Paranjpe S, et al. Pharmacologic inhibition of epidermal growth factor receptor suppresses nonalcoholic fatty liver disease in a murine fast‐food diet model. Hepatology 2019; 70: 1546–1563.
Publication types
MeSH terms
Substances
Grants and funding
- EHDG1703/CIBEREHD, National Biomedical Research Institute on Liver and Gastrointestinal Diseases
- CERCA Programme/Generalitat de Catalunya
- CIVP20A6593/Fundacion Ramon Areces
- PID2019-108651RJ-I00/Agencia Estatal de Investigación, Ministerio de Ciencia e Innovación, Spain
- PID2021-122551OB-100/Agencia Estatal de Investigación, Ministerio de Ciencia e Innovación, Spain
- PID-2021-122766OB-100/Agencia Estatal de Investigación, Ministerio de Ciencia e Innovación, Spain
- RTC2019-007125-1/Agencia Estatal de Investigación, Ministerio de Ciencia e Innovación, Spain
- RTI2018-094052-B-100/Agencia Estatal de Investigación, Ministerio de Ciencia e Innovación, Spain
- RTI2018-094079-B-100/Agencia Estatal de Investigación, Ministerio de Ciencia e Innovación, Spain
- RTI2018-099098-B-100/Agencia Estatal de Investigación, Ministerio de Ciencia e Innovación, Spain
- RYC2021-034121-I/Agencia Estatal de Investigación, Ministerio de Ciencia e Innovación, Spain
- European Regional Development Fund
- Instituto de Salud Carlos III
LinkOut - more resources
Full Text Sources
Molecular Biology Databases
Research Materials
Miscellaneous
